ClinicalTrials.gg
RecruitingNCT06569472Updated Aug 26, 2024

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

A Phase 1 interventional study of CD19-targetd CAR-T in Juvenile Dermatomyositis, sponsored by Chongqing Precision Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Chongqing Precision Biotech Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies in Dermatomyositis with a site in China — 17 open to participants now, 18 under way, 4 of them phase 3. Dermatomyositis · China.

Planned enrollment
22nd of 24
10 · median 88
Started
2024
with 5 others
Phase 1
8 of 31
6 open now
Primary completion
2027-07
later than 10 of 17 live
Registered
22nd of 31
by date
Lead sponsor
4 of 31
Chongqing Precision Biotech Co., Ltd

Among the 31 studies in Dermatomyositis with a site in China, this one is the 22nd largest by planned enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 10 of the 17 other live ones, and was the 22nd registered.

Dermatomyositis

184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.

Browse Dermatomyositis studies →

Open to participants now

17 of the 31 studies in Dermatomyositis with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Dermatomyositis with a site in China, or all of them as a file.
02

Study summary

This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).

Read the detailed description

juvenile dermatomyositis (JDM) is a non-suppurative chronic autoimmune disease and the most common type of juvenile idiopathic inflammatory myopathy.Despite the active treatment measures, some JDM patients are still intolerant or unresponsive to the treatment, resulting in a high disability and mortality rate.Because CD19 is widely expressed on the surface of B lymphocytes, CD19 CAR-T can also cause deep depletion of other CD19+ B cells while killing cancer cells, which is expected to achieve immune reconstruction in patients with autoimmune diseases, and completely change the status quo that such patients need to take hormones and immunosuppressants for a long time.

03

Conditions studied

  • Juvenile Dermatomyositis

Browse trials for

Keywords

  • CAR-T
  • CD19
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥5 years and \<17 years old
  2. To meet the diagnostic criteria of JDM, four or five of the following criteria must be met:① symmetrical proximal muscle weakness; ②Characteristic skin changes, including positive dermatitis (purplish red rash on upper eyelid with periorbital edema) and Gottron papules (red patchy squamous papules on the back of knuckles); ③ The level of one muscle enzyme in serum was increased; ④ Positive myositis antibody; ⑤Electromyography shows denervation and myopathy; ⑥ Muscle showed necrosis and inflammation.
  3. The classification criteria of RJDM must meet ① and any of the criteria②-④: ① Patients who are intolerant or unresponsive to and at least 2 , adequate hormone therapy and duration of at least 6 months; ② The disease progresses rapidly and/or involves organs such as lungs, heart and gastrointestinal tract; ③ Calcification of subcutaneous or muscle and joint tissues; ④ Repeated rashes or skin ulcers.
  4. myositis specific antibody positive, defined as MDA-5, NXP2, TIF-1γ, Ro-52 and any other positive;
  5. If the patient has SRP or HMGCR antibody positive immune-mediated necrotizing myopathy equivalent to RJDM, the inclusion criteria of (2) - (4) can be met.
  6. The functions of important organs are basically normal:

    ① Cardiac function: (LVEF) ≥55%, no obvious abnormality in ;

    ② Renal function: ≥30ML/min/1.73m2;

    ③ Liver function: and ALT≤3.0 , total ≤2.0×ULN;

    ④ Lung function: Lung function is basically normal, SpO2≥92%;

  7. Have the criteria for simple or intravenous blood collection, and no other for cell collection;
  8. The subject of childbearing age has a negative urine pregnancy test result and agrees to take effective measures during the test period until 1 year after the infusion;
  9. The patient or his/her guardian agrees to participate in this clinical trial and signs an indicating that he/she understands the purpose and procedure of this clinical trial and is willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Had previously received CAR T cell therapy;
  2. Have other or rheumatic diseases other than JDM;
  3. primary immunodeficiency or severe secondary immunodeficiency that has not been corrected;
  4. accompanied by serious infectious diseases, including but not limited to active tuberculosis, latent tuberculosis infection, active viral hepatitis, etc.;
  5. Evidence of active malignant disease or diagnosis of malignant tumor (including hematological and solid tumors, except resected and cured skin basal cell carcinoma)
  6. Congenital heart disease or history of acute myocardial infarction within 6 months before screening, or severe arrhythmias (including multi-source frequent supraventricular tachycardia, ventricular tachycardia, etc.); Or combined with a large number of pericardial effusion, serious myocarditis, etc.; Or patients with unstable vital signs who need hypertensive drugs to maintain their blood pressure;
  7. suffering from other diseases that require long-term use of or ;
  8. There is an active or uncontrollable infection that requires systemic treatment within 1 week prior to screening;
  9. Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; Acute (GVHD) of grade 2 or above was present within 2 weeks prior to screening;
  10. surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for (HIV) antibodies; Or syphilis test positive; Or cytomegalovirus (CMV) DNA test positive;
  11. Had received within 4 weeks prior to screening;
  12. Positive blood pregnancy test;
  13. Patients with known malignant diseases such as tumors before screening;
  14. Patients who had participated in other clinical trials within 3 months prior to enrollment;
  15. Situations in which other investigators consider it inappropriate to participate in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    CD19-targeted CAR-T

    The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).

    Biological: CD19-targetd CAR-T

Interventions

  • BiologicalCD19-targetd CAR-T

    Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of CAR-T in the treatment of refractory juvenile dermatomyositis [Safety and Tolerability]

    The incidence of adverse events after CAR-T cell infusion was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).including the type, frequency and severity of adverse events

    Time frame: 28 days

  2. To evaluate the efficacy of CAR-T in the treatment of refractory juvenile dermatomyositis [Effectiveness]

    Disease improvement rate: The number of subjects who achieved disease improvement as a percentage of all subjects who received transfusions.

    Time frame: 2month,3months

  3. Duration of Response (DOR) of CAR-T treatment in the treatment of refractory juvenile dermatomyositis [Effectiveness]

    DOR will be assessed from the first assessment of remission to the first assessment of recurrence or progression of the disease or death from any cause

    Time frame: 2 years

Secondary outcomes

  1. AUCS of CD19 CAR-T cells [Cell dynamics]

    AUCS is defined as the area under the curve in 90 days

    Time frame: 3 months

  2. CMAX of CD19 CAR-T cells [Cell dynamics]

    CMAX is defined as the highest concentration of CEA CAR-T cells expanded in peripheral blood

    Time frame: 3 months

  3. TMAX of CD19 CAR-T cells[Cell dynamics]

    TMAX is defined as the time to reach the highest concentration

    Time frame: 3 months

Other outcomes

  1. To evaluate the effects of CD19-targeting CAR T cell preparations on the weight of children

    Weight in kilograms were monitored after transfusion until subjects reached 18 years of age

    Time frame: 2 years

  2. To evaluate the effects of CD19-targeting CAR T cell preparations on the height of children

    Height in meters were monitored after transfusion until subjects reached 18 years of age

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 26, 2024
StartActual
Jul 2, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06569472
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Jul 2, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Aug 26, 2024

Study contacts

Meiping Lu, M.D
Contact
meipinglu@zju.edu.cn
13685773988
Meiping Lu, M.D
principal investigator · Children's Hospital, Zhejiang University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion